Host |
Mouse |
Klon |
TAL 1B5 |
Format |
concentrated |
Methode |
P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
cell membrane |
HLA-DR
|
Biocare Medical |
TAL 1B5 |
0. ml |
concentrated |
CE/IVD |
ACI3273A |
-
|
Host |
Mouse |
Klon |
TAL 1B5 |
Format |
concentrated |
Methode |
P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
cell membrane |
HLA-DR
|
Biocare Medical |
TAL 1B5 |
1 ml |
concentrated |
CE/IVD |
ACI3273C |
-
|
Host |
Mouse |
Klon |
TAL 1B5 |
Format |
Ready-to-use |
Methode |
P |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
cell membrane |
HLA-DR
|
Biocare Medical |
TAL 1B5 |
7 ml |
Ready-to-use |
CE/IVD |
ALI3273G7 |
-
|
Host |
Mouse |
Klon |
TAL 1B5 |
Format |
Ready-to-use |
Methode |
P |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
cell membrane |
HLA-DR
|
Biocare Medical |
TAL 1B5 |
6 ml |
Ready-to-use |
CE/IVD |
API3273 |
-
|
Host |
Mouse |
Klon |
TAL 1B5 |
Format |
Ready-to-use |
Methode |
P |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
cell membrane |
HLA-DR
|
Biocare Medical |
TAL 1B5 |
6 ml |
Ready-to-use |
CE/IVD |
AVI3273G |
-
|
Host |
Mouse |
Klon |
CR3/43 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cell Membrane |
HLA-DR (β chain of DP, DQ & DR)
|
Diagnostic Biosystems |
CR3/43 |
1 ml |
Concentrate |
RUO |
MOB069R |
-
|
Host |
Mouse |
Klon |
CR3/43 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cell Membrane |
HLA-DR (β chain of DP, DQ & DR)
|
Diagnostic Biosystems |
CR3/43 |
0.1 ml |
Concentrate |
RUO |
MOB069R-01 |
-
|
Host |
Mouse |
Klon |
CR3/43 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cell Membrane |
HLA-DR (β chain of DP, DQ & DR)
|
Diagnostic Biosystems |
CR3/43 |
0.5 ml |
Concentrate |
RUO |
MOB069R-05 |
-
|
Host |
Mouse |
Klon |
CR3/43 |
Format |
Ready-to-use |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cell Membrane |
HLA-DR (β chain of DP, DQ & DR)
|
Diagnostic Biosystems |
CR3/43 |
6 ml |
Ready-to-use |
RUO |
PDM082 |
-
|
Host |
Mouse |
Klon |
MEM-G/1 |
Format |
Purified |
Methode |
WB, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Human Placenta |
Isotyp |
Mouse IgG1 |
HLA-G
|
Zytomed Systems GmbH |
MEM-G/1 |
200 µg |
Purified |
RUO |
608-0223 |
-
|
Host |
Mouse |
Klon |
HMB45+M2-7C10+M2-9E3+T311 |
Format |
Ready-to-use |
Methode |
F, P |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
Mouse Ig |
Lokalisation |
Cytoplasm |
HMB45 + MART-1 + Tyrosinase
|
Biocare Medical |
HMB45+M2-7C10+M2-9E3+T311 |
6 ml |
Ready-to-use |
CE/IVD |
VP165 |
-
|
Host |
Mouse |
Klon |
CAMVR-1 & C1P5 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
HPV infected cells of tissue |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a/k + IgG1/k |
Verdünnung |
HPV16 major capsid protein L1 and recombinant full-length protein corresponding to HPV16 E6 & HPV18 E6 |
Lokalisation |
Nuclei of infected cells |
HPV
|
Zeta Corporation |
CAMVR-1 & C1P5 |
1ml |
Concentrate |
RUO |
Z2657ML-R |
-
|
Host |
Mouse |
Klon |
CAMVR-1 & C1P5 |
Format |
r-t-u |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
HPV infected cells of tissue |
Verdünnung |
- |
Isotyp |
IgG2a/k + IgG1/k |
Verdünnung |
HPV16 major capsid protein L1 and recombinant full-length protein corresponding to HPV16 E6 & HPV18 E6 |
Lokalisation |
Nuclei of infected cells |
HPV
|
Zeta Corporation |
CAMVR-1 & C1P5 |
7ml |
r-t-u |
RUO |
Z2657MP-R |
-
|
Host |
Mouse |
Klon |
CAMVR-1 & C1P5 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
HPV infected cells of tissue |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a/k + IgG1/k |
Verdünnung |
HPV16 major capsid protein L1 and recombinant full-length protein corresponding to HPV16 E6 & HPV18 E6 |
Lokalisation |
Nuclei of infected cells |
HPV
|
Zeta Corporation |
CAMVR-1 & C1P5 |
0.5 ml |
Concentrate |
RUO |
Z2657MS-R |
-
|
Host |
Mouse |
Klon |
CAMVR-1 & C1P5 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
HPV infected cells of tissue |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a/k + IgG1/k |
Verdünnung |
HPV16 major capsid protein L1 and recombinant full-length protein corresponding to HPV16 E6 & HPV18 E6 |
Lokalisation |
Nuclei of infected cells |
HPV
|
Zeta Corporation |
CAMVR-1 & C1P5 |
0.1 ml |
Concentrate |
RUO |
Z2657MT-R |
-
|
Host |
Mouse |
Klon |
CAMVIR-1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
HPV Infected Cervix Tissue |
Verdünnung |
1:25 - 1:50 |
Isotyp |
IgG2a |
Lokalisation |
Nucleus |
HPV 16, L1 (Papillomavirus Type 16)
|
Diagnostic Biosystems |
CAMVIR-1 |
1 ml |
Concentrate |
CE/IVD |
MOB394 |
-
|
Host |
Mouse |
Klon |
CAMVIR-1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
HPV Infected Cervix Tissue |
Verdünnung |
1:25 - 1:50 |
Isotyp |
IgG2a |
Lokalisation |
Nucleus |
HPV 16, L1 (Papillomavirus Type 16)
|
Diagnostic Biosystems |
CAMVIR-1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB394-01 |
-
|
Host |
Mouse |
Klon |
CAMVIR-1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
HPV Infected Cervix Tissue |
Verdünnung |
1:25 - 1:50 |
Isotyp |
IgG2a |
Lokalisation |
Nucleus |
HPV 16, L1 (Papillomavirus Type 16)
|
Diagnostic Biosystems |
CAMVIR-1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB394-05 |
-
|
Host |
Mouse |
Klon |
CAMVIR-1 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
HPV Infected Cervix Tissue |
Verdünnung |
- |
Isotyp |
IgG2a |
Lokalisation |
Nucleus |
HPV 16, L1 (Papillomavirus Type 16)
|
Diagnostic Biosystems |
CAMVIR-1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM166 |
-
|
Host |
Rabbit |
Klon |
ZR152 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
HIER or PIER |
Positivkontrolle |
HCC |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa400-600) of human HSPA1B protein |
Lokalisation |
Nucleus and cytoplasm |
HSP70
|
Zeta Corporation |
ZR152 |
1 ml |
Concentrate |
CE/IVD |
Z2694RL |
-
|
Host |
Rabbit |
Klon |
ZR152 |
Format |
ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
HIER or PIER |
Positivkontrolle |
HCC |
Verdünnung |
--- |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa400-600) of human HSPA1B protein |
Lokalisation |
Nucleus and cytoplasm |
HSP70
|
Zeta Corporation |
ZR152 |
7 ml |
ready-to-use |
CE/IVD |
Z2694RP |
-
|
Host |
Rabbit |
Klon |
ZR152 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
HIER or PIER |
Positivkontrolle |
HCC |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa400-600) of human HSPA1B protein |
Lokalisation |
Nucleus and cytoplasm |
HSP70
|
Zeta Corporation |
ZR152 |
0.5 ml |
Concentrate |
CE/IVD |
Z2694RS |
-
|
Host |
Rabbit |
Klon |
ZR152 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
HIER or PIER |
Positivkontrolle |
HCC |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa400-600) of human HSPA1B protein |
Lokalisation |
Nucleus and cytoplasm |
HSP70
|
Zeta Corporation |
ZR152 |
0.1 ml |
Concentrate |
CE/IVD |
Z2694RT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
HSV Infected Lung |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm, nucleus |
HSV I (Herpes Simplex Virus)
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR032 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
HSV Infected Lung |
Verdünnung |
1:75 - 1:200 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm, nucleus |
HSV I (Herpes Simplex Virus)
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP018 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
HSV Infected Lung |
Verdünnung |
1:75 - 1:200 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm, nucleus |
HSV I (Herpes Simplex Virus)
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP018-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
HSV Infected Lung |
Verdünnung |
1:75 - 1:200 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm, nucleus |
HSV I (Herpes Simplex Virus)
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP018-05 |
-
|
Host |
Rabbit + Mouse |
Klon |
polyclonal + DBM15.69 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
HSV Infected Tissue |
Verdünnung |
- |
Isotyp |
Rabbit Ig + Mouse IgG1 |
Verdünnung |
Whole rabbit corneal cells, infected with herpes simplex virus type I (strain Mac Intyre) and BALB/C mice immunized with Parker strain of herpes simplex virus type 2. |
Lokalisation |
Cytoplasm, nucleus |
HSV I & II (Herpes Simplex Virus)
|
Diagnostic Biosystems |
polyclonal + DBM15.69 |
6 ml |
Ready-to-use |
CE/IVD |
PDRM001 |
-
|
Host |
Mouse |
Klon |
0192 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
HSV infected tissue |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 |
Verdünnung |
Synthesized peptide specific to glycoprotein D |
Lokalisation |
Cytoplasm or nucleus |
HSV II
|
Zeta Corporation |
0192 |
1ml |
Concentrate |
RUO |
Z2831ML-R |
-
|
Host |
Mouse |
Klon |
DBM15.69 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Infected lung |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 |
Verdünnung |
BALB/C mice were immunized with Parker strain of herpes simplex virus type 2 |
Lokalisation |
Cytoplasm, nucleus |
HSV II (Herpes simplex Virus)
|
Diagnostic Biosystems |
DBM15.69 |
1 ml |
Concentrate |
CE/IVD |
MOB542 |
-
|
Host |
Mouse |
Klon |
DBM15.69 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Infected lung |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 |
Verdünnung |
BALB/C mice were immunized with Parker strain of herpes simplex virus type 2 |
Lokalisation |
Cytoplasm, nucleus |
HSV II (Herpes simplex Virus)
|
Diagnostic Biosystems |
DBM15.69 |
0.1 ml |
Concentrate |
CE/IVD |
MOB542-01 |
-
|
Host |
Mouse |
Klon |
DBM15.69 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Infected lung |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 |
Verdünnung |
BALB/C mice were immunized with Parker strain of herpes simplex virus type 2 |
Lokalisation |
Cytoplasm, nucleus |
HSV II (Herpes simplex Virus)
|
Diagnostic Biosystems |
DBM15.69 |
0.5 ml |
Concentrate |
CE/IVD |
MOB542-05 |
-
|
Host |
Mouse |
Klon |
DBM15.69 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Infected lung |
Verdünnung |
- |
Isotyp |
IgG1 |
Verdünnung |
BALB/C mice were immunized with Parker strain of herpes simplex virus type 2 |
Lokalisation |
Cytoplasm, nucleus |
HSV II (Herpes simplex Virus)
|
Diagnostic Biosystems |
DBM15.69 |
6 ml |
Ready-to-use |
CE/IVD |
PDM542 |
-
|
Host |
Mouse |
Klon |
DBM15.69 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Infected lung |
Verdünnung |
- |
Isotyp |
IgG1 |
Verdünnung |
BALB/C mice were immunized with Parker strain of herpes simplex virus type 2 |
Lokalisation |
Cytoplasm, nucleus |
HSV II (Herpes simplex Virus)
|
Diagnostic Biosystems |
DBM15.69 |
25 ml |
Ready-to-use |
CE/IVD |
PDM542-25 |
-
|
Host |
Mouse |
Klon |
10A3 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
HSV infected tissue |
Verdünnung |
1:50 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
etergent-solubilized herpes simplex virus (HSV) type 1 infected cells |
Lokalisation |
Cytoplasm or nucleus |
HSV1
|
Zeta Corporation |
10A3 |
1ml |
Concentrate |
CE/IVD |
Z2215ML |
-
|
Host |
Mouse |
Klon |
10A3 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
HSV infected tissue |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
etergent-solubilized herpes simplex virus (HSV) type 1 infected cells |
Lokalisation |
Cytoplasm or nucleus |
HSV1
|
Zeta Corporation |
10A3 |
7 ml |
Ready-to-use |
CE/IVD |
Z2215MP |
-
|
Host |
Mouse |
Klon |
10A3 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
HSV infected tissue |
Verdünnung |
1:50 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
etergent-solubilized herpes simplex virus (HSV) type 1 infected cells |
Lokalisation |
Cytoplasm or nucleus |
HSV1
|
Zeta Corporation |
10A3 |
0.5 ml |
Concentrate |
CE/IVD |
Z2215MS |
-
|
Host |
Mouse |
Klon |
10A3 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
HSV infected tissue |
Verdünnung |
1:50 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
etergent-solubilized herpes simplex virus (HSV) type 1 infected cells |
Lokalisation |
Cytoplasm or nucleus |
HSV1
|
Zeta Corporation |
10A3 |
0.1 ml |
Concentrate |
CE/IVD |
Z2215MT |
-
|
Host |
Mouse |
Klon |
AIF1 |
Format |
concentrate |
Methode |
F, P |
Vorbehandlung |
Tris EDTA Puffer, pH 9,0 |
Positivkontrolle |
Spleen |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1,kappa |
Verdünnung |
Purified fragment of human recombinant AIF1 protein (around aa 1-146) (exact sequence is proprietary) |
Lokalisation |
Cytoplasmic and Cell Surface |
Iba1 (AIF1)
|
Diagnostic Biosystems |
AIF1 |
1 ml |
concentrate |
CE/IVD |
MOB602 |
-
|
Host |
Mouse |
Klon |
AIF1 |
Format |
ready-to-use |
Methode |
F, P |
Vorbehandlung |
Tris EDTA Puffer, pH 9,0 |
Positivkontrolle |
Spleen |
Verdünnung |
--- |
Isotyp |
Mouse IgG1,kappa |
Verdünnung |
Purified fragment of human recombinant AIF1 protein (around aa 1-146) (exact sequence is proprietary) |
Lokalisation |
Cytoplasmic and Cell Surface |
Iba1 (AIF1)
|
Diagnostic Biosystems |
AIF1 |
6 ml |
ready-to-use |
CE/IVD |
PDM602 |
-
|
Host |
Mouse |
Klon |
IHC132 |
Format |
concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Astrocytoma |
Verdünnung |
1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic |
IDH1 R132H
|
Biocare Medical |
IHC132 |
0.1 ml |
concentrate |
CE/IVD |
ACI3253A |
-
|
Host |
Mouse |
Klon |
IHC132 |
Format |
concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Astrocytoma |
Verdünnung |
1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic |
IDH1 R132H
|
Biocare Medical |
IHC132 |
1 ml |
concentrate |
CE/IVD |
ACI3253C |
-
|
Host |
Mouse |
Klon |
IHC132 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Astrocytoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic |
IDH1 R132H
|
Biocare Medical |
IHC132 |
7 ml |
Ready-to-use |
CE/IVD |
ALI3253G7 |
-
|
Host |
Mouse |
Klon |
IHC132 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Astrocytoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic |
IDH1 R132H
|
Biocare Medical |
IHC132 |
6 ml |
Ready-to-use |
CE/IVD |
API3253AA |
-
|
Host |
Mouse |
Klon |
HMab-1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Human Glioma Tissue |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cytoplasmic, nucleus |
IDH1 R132H
|
Diagnostic Biosystems |
HMab-1 |
1 ml |
Concentrate |
RUO |
MOB580R |
-
|
Host |
Mouse |
Klon |
HMab-1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Human Glioma Tissue |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cytoplasmic, nucleus |
IDH1 R132H
|
Diagnostic Biosystems |
HMab-1 |
0.1 ml |
Concentrate |
RUO |
MOB580R-01 |
-
|
Host |
Mouse |
Klon |
HMab-1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Human Glioma Tissue |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cytoplasmic, nucleus |
IDH1 R132H
|
Diagnostic Biosystems |
HMab-1 |
0.5 ml |
Concentrate |
RUO |
MOB580R-05 |
-
|
Host |
Mouse |
Klon |
HMab-1 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Human Glioma Tissue |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cytoplasmic, nucleus |
IDH1 R132H
|
Diagnostic Biosystems |
HMab-1 |
6 ml |
Ready-to-use |
RUO |
PDM580R |
-
|
Host |
Mouse |
Klon |
SMab-1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Human Glioma Tissue |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cytoplasmic, nucleus |
IDH1 R132S
|
Diagnostic Biosystems |
SMab-1 |
1 ml |
Concentrate |
RUO |
MOB582R |
-
|
Host |
Mouse |
Klon |
SMab-1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Human Glioma Tissue |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cytoplasmic, nucleus |
IDH1 R132S
|
Diagnostic Biosystems |
SMab-1 |
0.1 ml |
Concentrate |
RUO |
MOB582R-01 |
-
|